Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06620029
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
BMX-001 Paclitaxel in Adult Patients With Advanced Recurrent Metastatic Ovarian or Endometrial Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 12 Open-label Clinical Trial to Evaluate Safety and Efficacy of Combination Paclitaxel and BMX-001 in Adult Patients With Advanced Recurrent Metastatic Ovarian or Endometrial Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripheral neuropathy CIPN in patients with recurrent ovarian and endometrial cancers which are among the most lethal gynecologic malignancies worldwide The study focuses on BMX-001 a redox-active manganese metalloporphyrin compound that uniquely combines the ability to enhance anti-tumor efficacy and protect normal tissues from the toxic effects of chemotherapy specifically paclitaxel PTX PTX despite being a cornerstone of treatment is associated with significant dose-limiting neurotoxicity which severely impacts patients quality of life and limits the use of subsequent therapies BMX-001 has demonstrated potential in preclinical models to not only augment the anti-tumor effects of PTX but also reduce PTX-induced neuropathy
The research will be conducted through a single-site Phase 12 clinical trial led by the Duke Cancer Institute The trial aims to determine the recommended Phase 2 dose of BMX-001 when combined with weekly PTX and to evaluate the clinical activity of this combination therapy Specifically the trial will assess the safety tolerability and potential to double the dose of BMX-001 which is hypothesized to further enhance the efficacy of PTX without increasing toxicity The study39s specific aims include establishing the recommended dose for expansion assessing objective response rates ORR and quantifying the reduction in PTX-induced neurotoxicity using validated questionnaires and monofilament testing The project also incorporates the analysis of circulating tumor DNA ctDNA as a biomarker for treatment response adding a layer of precision to the evaluation of the therapy response impact on tumor burden
The outcomes of this research have the potential to significantly improve treatment protocols for patients with chemo-resistant gynecologic cancers by offering a therapy that enhances tumor control while protecting against debilitating side effects Successful completion of this trial will lay the groundwork for larger definitive trials and may extend the benefits of BMX-001 to other solid tumors ultimately contributing to better survival outcomes and quality of life for a broader patient population
The research will be conducted through a single-site Phase 12 clinical trial led by the Duke Cancer Institute The trial aims to determine the recommended Phase 2 dose of BMX-001 when combined with weekly PTX and to evaluate the clinical activity of this combination therapy Specifically the trial will assess the safety tolerability and potential to double the dose of BMX-001 which is hypothesized to further enhance the efficacy of PTX without increasing toxicity The study39s specific aims include establishing the recommended dose for expansion assessing objective response rates ORR and quantifying the reduction in PTX-induced neurotoxicity using validated questionnaires and monofilament testing The project also incorporates the analysis of circulating tumor DNA ctDNA as a biomarker for treatment response adding a layer of precision to the evaluation of the therapy response impact on tumor burden
The outcomes of this research have the potential to significantly improve treatment protocols for patients with chemo-resistant gynecologic cancers by offering a therapy that enhances tumor control while protecting against debilitating side effects Successful completion of this trial will lay the groundwork for larger definitive trials and may extend the benefits of BMX-001 to other solid tumors ultimately contributing to better survival outcomes and quality of life for a broader patient population
Detailed Description:
This clinical trial is a proof-of-concept Phase 12 study aimed at establishing the recommended Phase 2 dose RP2D of BMX-001 when administered in combination with weekly paclitaxel PTX in patients with advanced metastatic ovarian or endometrial cancer The rationale for this open-label trial is twofold 1 response rates to weekly PTX in patients with platinum-resistant ovarian cancer PROC are generally low and when a response is achieved its duration is often short necessitating novel therapeutic approaches to improve outcomes 2 weekly PTX is associated with dose-limiting side effects particularly chemotherapy-induced peripheral neuropathy CIPN which significantly impacts patients quality of life
The trial includes a dose-finding stage designed to assess the safety and dose-limiting toxicities DLTs of the combination treatment The study will use a Bayesian Optimal Interval BOIN design to test the safety of weekly BMX-001 injections in combination with weekly PTX The goal is to determine if BMX-001 can be safely administered at increasing doses while enhancing both the efficacy of treatment as well as diminishing chemotherapy side effects in patients with recurrent advanced ovarian and endometrial cancers
Patients in the dose-escalation phase will receive up to 16 doses over an 8-week period All participants will receive PTX at a dose of 80 mgm² on the first day of each weekly cycle The starting dose of BMX-001 will be 28 mg subcutaneously on the first day of each weekly cycle Cohorts of three patients will be treated and evaluated for DLTs sequentially If the starting dose is well-tolerated subsequent cohorts will escalate to higher doses with a maximum of 28 mg followed by 28 mg BMX-001 given 4-6 hours apart on the same day each week Should any patients at Dose Level 1 experience DLTs the dose will be de-escalated according to the BOIN design to Dose Level -1 14 mgweek and if necessary further to Dose Level -2 7 mgweek which is the final de-escalation dose group
Upon completion of the dose-finding phase an expansion cohort will be enrolled at the RP2D The study will enroll up to 27 patients in this trial The primary outcome measure is to establish the RP2D of BMX-001 in combination with PTX Secondary outcomes include evaluation of preliminary efficacy based on objective response rate ORR using RECIST v 11 per investigator assessment endpoints and obtaining a description of patient-reported outcomes of health related quality of life HRQoL quality of life QoL using FACTGOG-NTX Questionnaire and monofilament testing
Other outcome measures to be assessed in all patients include characterization of the pharmacokinetic profile of BMX-001 when delivered in combination with PTX in recurrent ovarian or endometrial cancer and also to assess correlations between B cell lymphomaleukemia 2 BCL2 Nrf2 TNF-alpha and NFkB RNA and protein expression and activation ctDNA and clinical responses This initial single arm trial is limited to 27 subjects based on the funds available in this SBIR In spite of the small sample size the study expects to obtain sufficient data to enable design a subsequent randomized trial that would meet registration requirements
The trial includes a dose-finding stage designed to assess the safety and dose-limiting toxicities DLTs of the combination treatment The study will use a Bayesian Optimal Interval BOIN design to test the safety of weekly BMX-001 injections in combination with weekly PTX The goal is to determine if BMX-001 can be safely administered at increasing doses while enhancing both the efficacy of treatment as well as diminishing chemotherapy side effects in patients with recurrent advanced ovarian and endometrial cancers
Patients in the dose-escalation phase will receive up to 16 doses over an 8-week period All participants will receive PTX at a dose of 80 mgm² on the first day of each weekly cycle The starting dose of BMX-001 will be 28 mg subcutaneously on the first day of each weekly cycle Cohorts of three patients will be treated and evaluated for DLTs sequentially If the starting dose is well-tolerated subsequent cohorts will escalate to higher doses with a maximum of 28 mg followed by 28 mg BMX-001 given 4-6 hours apart on the same day each week Should any patients at Dose Level 1 experience DLTs the dose will be de-escalated according to the BOIN design to Dose Level -1 14 mgweek and if necessary further to Dose Level -2 7 mgweek which is the final de-escalation dose group
Upon completion of the dose-finding phase an expansion cohort will be enrolled at the RP2D The study will enroll up to 27 patients in this trial The primary outcome measure is to establish the RP2D of BMX-001 in combination with PTX Secondary outcomes include evaluation of preliminary efficacy based on objective response rate ORR using RECIST v 11 per investigator assessment endpoints and obtaining a description of patient-reported outcomes of health related quality of life HRQoL quality of life QoL using FACTGOG-NTX Questionnaire and monofilament testing
Other outcome measures to be assessed in all patients include characterization of the pharmacokinetic profile of BMX-001 when delivered in combination with PTX in recurrent ovarian or endometrial cancer and also to assess correlations between B cell lymphomaleukemia 2 BCL2 Nrf2 TNF-alpha and NFkB RNA and protein expression and activation ctDNA and clinical responses This initial single arm trial is limited to 27 subjects based on the funds available in this SBIR In spite of the small sample size the study expects to obtain sufficient data to enable design a subsequent randomized trial that would meet registration requirements
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None